Wedbush Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know

Wedbush has decided to maintain its Outperform rating of 2seventy bio TSVT and lower its price target from $28.00 to $21.00.

Shares of 2seventy bio are trading down 0.1% over the last 24 hours, at $9.81 per share.

A move to $21.00 would account for a 114.07% increase from the current share price.

About 2seventy bio

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.